Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accounts Payables (2016 - 2025)

Northwest Biotherapeutics' Accounts Payables history spans 16 years, with the latest figure at $30.8 million for Q4 2025.

  • Quarterly results put Accounts Payables at $30.8 million for Q4 2025, up 81.6% from a year ago — trailing twelve months through Dec 2025 was $30.8 million (up 81.6% YoY), and the annual figure for FY2025 was $30.8 million, up 81.6%.
  • Accounts Payables for Q4 2025 was $30.8 million at Northwest Biotherapeutics, up from $26.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $30.8 million in Q4 2025 to a low of $7.0 million in Q4 2021.
  • The 5-year median for Accounts Payables is $12.0 million (2023), against an average of $14.0 million.
  • The sharpest move saw Accounts Payables fell 11.15% in 2022, then skyrocketed 81.6% in 2025.
  • Year by year, Accounts Payables stood at $7.0 million in 2021, then skyrocketed by 53.2% to $10.7 million in 2022, then fell by 4.15% to $10.2 million in 2023, then soared by 65.65% to $17.0 million in 2024, then skyrocketed by 81.6% to $30.8 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $30.8 million, $26.9 million, and $23.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.